Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ISRT vs IFRT in Limited-stage DLBCL
NCT02449265Phase 3Unknown
- Sponsor
- Wuhan University
- Start
- Oct 2015
- Primary completion
- Oct 2019
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial (2 arms), sponsored by Wuhan University. Primary endpoints: Progression-free survival at 100 months and Adverse events with grade 3 or 4 at 24 months. Status: unknown.
Beyond the preview
Go deeper on NCT02449265.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02449265.